The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research. Issue 5 (29th November 2018)

• Record Type: Journal Article
• Authors: Djukanovic, Ratko; Adcock, Ian M.; Anderson, Gary; Bel, Elisabeth H.; Canonica, Giorgio W.; Cao, Hui; Chung, Kian Fan; Davies, Donna E.; Genton, Céline; Gibson-Latimer, Toni; Hamerlijnck, Dominique; Heuvelin, Elise; Louis, Renaud; Korn, Stephanie; Kots, Maxim; Kwon, Namhee; Naddaf, Riad; Wagers, Scott S.
• Other Names: author non-byline.; Djukanovic Ratko author non-byline.; Bel Elisabeth author non-byline.; Hamerlijnck Dominique author non-byline.; Gibson-Latimer Toni author non-byline.; Adler Joan author non-byline.; Ayre Stephanie author non-byline.; Bednarczyk Line author non-byline.; Brons Anette author non-byline.; Davin Elizabeth author non-byline.; Decarlo Giuseppe author non-byline.; Dyett Karyss author non-byline.; Frankemölle Betty author non-byline.; Fulton Olivia author non-byline.; Hilliyard Kenneth author non-byline.; Lycett Kelly author non-byline.; Otker Jacqueline author non-byline.; Parkinson Jasmine author non-byline.; Slaughter Rachelle author non-byline.; Cao Hui author non-byline.; Kots Maxim author non-byline.; Kwon Namhee author non-byline.; Naddaf Riad author non-byline.; Bieksiene Kristina author non-byline.; Bourdin Arnaud author non-byline.; Costello Richard author non-byline.; Dahlén Barbro author non-byline.; Doberer Daniel author non-byline.; Joos Guy author non-byline.; Lazic Zorica author non-byline.; Lehtimäki Lauri author non-byline.; Leuppi Joerg author non-byline.; Lúðvíksdóttir Dora author non-byline.; Porsbjerg Celeste author non-byline.; Sedlak Vratislav author non-byline.; Sergejeva Svetlana author non-byline.; Skrgat Sabina author non-byline.; Brinke Anneke ten author non-byline.; Tudoric Neven author non-byline.; Heffler Enrico author non-byline.; Kankaaranta Hannu author non-byline.; Coleman Courtney author non-byline.; Genton Celine author non-byline.; Heuvelin Elise author non-byline.; Powell Pippa author non-byline.; Usmani Omar author non-byline.; Wagers Scott author non-byline.; Adcock Ian author non-byline.; Anderson Gary author non-byline.; Chung Fan author non-byline.; Davies Donna author non-byline.; Dahlén Sven-Erik author non-byline.; Lambrecht Bart author non-byline.; Maitland-van der Zee Anke-Hilse author non-byline.; Poste Anthony author non-byline.; Sterk Peter author non-byline.; Wheelock Craig author non-byline.; Walter Canonica George author non-byline.; Gaga Mina author non-byline.; Heaney Liam author non-byline.; Horvath Ildiko author non-byline.; Humbert Marc author non-byline.; Kocks Jan Willem author non-byline.; Korn Stephanie author non-byline.; Kuna Piotr author non-byline.; Louis Renaud author non-byline.; Ramos-Barbon David author non-byline.; Sandström Thomas author non-byline.; Spanevello Antonio author non-byline.;
• Is Part Of: European respiratory journal. Volume 52:Issue 5(2018)
• Publication Date: 2018-11-29
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01671-2018
• Languages: English
• ISSNs: 0903-1936

Abstract

The past 30 years have seen major advances in the understanding of asthma mechanisms and the clinical introduction of effective medicines based on these pathways. The first major step-change occurred in the 1980s with the development of bronchial challenge as a research tool to dissect the airways inflammatory responses [1, 2]. The advent of bronchoscopy and sputum induction in the early 1990s, to study asthma pathology in vivo, enabled the description of characteristic features of airways inflammation and remodelling [3–6], while epidemiological and challenge studies showed viruses to be the main cause of asthma exacerbations [7, 8]. One of the greatest discoveries was the central role of Type-2 cytokines driven by the interleukin (IL)-4/IL-13 and IL-5 pathways, for which simple biomarkers, like sputum eosinophils and exhaled nitric oxide, were discovered [9, 10]. However, it was not until early 2000s that the basic science translated into fundamentally novel treatments, beginning the "era of biological treatments" with the anti-IgE antibody, omalizumab [11]. It took almost 15 years for the next biologics to arrive, targeting the pro-eosinophilic cytokine IL-5, showing how difficult drug development can be [12, 13]. SHARP (Severe Heterogeneous Asthma Research collaboration, Patient-centred) is set up to harmonise severe asthma management across Europe and unravel the heterogeneity of severe asthma in a patient-centred way http://ow.ly/s1x730mwLpk